{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:34:22Z","timestamp":1782484462418,"version":"3.54.5"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec019\">\n<jats:title>Background<\/jats:title>\n<jats:p>Beneficial effects of dopamine agonist treatment on migraine have been reported but remain to be properly tested. The aim of this study was to examine the effect of cabergoline as preventive treatment for migraine.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In a double-blind, placebo-controlled pilot study, 36 adults with \u2265\u2009 6 monthly migraine days were enrolled at Aarhus University Hospital. Following a 28-days baseline period, participants were randomized to receive cabergoline 0.5\u2009mg or placebo once weekly for 12 weeks as add-on treatment. An electronic headache diary was completed daily, and headache questionnaires and blood tests were collected at baseline and following the treatment period. Primary outcome was change in monthly migraine days. The trial was registered with ClinicalTrials.gov (NCT05525611).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec021\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of 101 assessed participants, 36 were enrolled. Baseline monthly migraine days were 13.6 (4.1) in the cabergoline group and 14.0 (5.3) in the placebo group. No significant overall difference in the reduction of monthly migraine days was observed. However, among participants with episodic migraine (n\u2009= 20), the mean (SE) reduction in monthly migraine days from baseline to the last 28 days of the treatment period was -5.4 (1.3) with cabergoline compared to -1.8 (0.9) with placebo (p\u2009=\u20090.04) [odds ratio: 0.79 (95% CI 0.65 \u2013 0.95), p\u2009=\u20090.014]. In participants with chronic migraine (n\u2009=\u200913), the reduction in monthly migraine days was not significantly different in the two groups. Patients\u2019 global impression of change significantly improved after cabergoline treatment as compared to placebo in the entire group of participants (p\u2009=\u20090.006). The number of participants with episodic migraine achieving \u2265\u2009 50% reduction in monthly migraine days tended to increase after cabergoline (p\u2009=\u20090.07). Adverse effects were reported by seven participants on cabergoline and four on placebo, none of which were serious.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec022\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Cabergoline significantly reduced monthly migraine days in episodic migraine without serious adverse effects, supporting further investigation into the use of cabergoline for migraine prevention.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0320937","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:07:39Z","timestamp":1743541659000},"page":"e0320937","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-4176","authenticated-orcid":true,"given":"Astrid Johannesson","family":"Hjelholt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming Winther","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Kasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"St\u00f8vring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-6380","authenticated-orcid":true,"given":"Troels Staehelin","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7408-1526","authenticated-orcid":true,"given":"Jens Otto Lunde","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"19","key":"pone.0320937.ref001","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"M Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0320937.ref002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"LJ Stovner","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"pone.0320937.ref003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"TJ Steiner","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"pone.0320937.ref004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"P Barbanti","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"pone.0320937.ref005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1526-4610.2011.02062.x","article-title":"Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium","volume":"52","author":"NE Kelley","year":"2012","journal-title":"Headache"},{"issue":"3","key":"pone.0320937.ref006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/WCO.0b013e3283378d5c","article-title":"Dopamine: what\u2019s new in migraine?","volume":"23","author":"AR Charbit","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"pone.0320937.ref007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.48.1.101","article-title":"Continuous bromocriptine therapy in menstrual migraine","volume":"48","author":"AG Herzog","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"pone.0320937.ref008","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1468-2982.1998.1804174.x","article-title":"Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data","volume":"18","author":"A Mascia","year":"1998","journal-title":"Cephalalgia"},{"issue":"17","key":"pone.0320937.ref009","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1212\/WNL.0000000000003861","article-title":"Dopamine D2\/D3 imbalance during migraine attack and allodynia in vivo","volume":"88","author":"AF DaSilva","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"pone.0320937.ref010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s10194-022-01469-x","article-title":"Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine","volume":"23","author":"W Zhang","year":"2022","journal-title":"J Headache Pain"},{"issue":"23","key":"pone.0320937.ref011","doi-asserted-by":"crossref","first-page":"16876","DOI":"10.3390\/ijms242316876","article-title":"Dopaminergic Projections from the Hypothalamic A11 Nucleus to the Spinal Trigeminal Nucleus Are Involved in Bidirectional Migraine Modulation","volume":"24","author":"C Li","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"pone.0320937.ref012","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0333102413515343","article-title":"Prolactinoma-associated headache and dopamine agonist treatment","volume":"34","author":"M-M Kallestrup","year":"2014","journal-title":"Cephalalgia"},{"issue":"4","key":"pone.0320937.ref013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11916-012-0267-x","article-title":"How to investigate and treat: headache and hyperprolactinemia","volume":"16","author":"G Bussone","year":"2012","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"pone.0320937.ref014","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12314","article-title":"Headache and pituitary disease: a systematic review","volume":"79","author":"I Kreitschmann-Andermahr","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"pone.0320937.ref015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10194-008-0016-z","article-title":"Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma","volume":"9","author":"D Bosco","year":"2008","journal-title":"J Headache Pain"},{"issue":"2","key":"pone.0320937.ref016","article-title":"Prolactin in headache and migraine: A systematic review of clinical studies","volume":"43","author":"MA-M Al-Karagholi","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"pone.0320937.ref017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10072-019-04035-7","article-title":"Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis","volume":"41","author":"A Noori-Zadeh","year":"2020","journal-title":"Neurol Sci"},{"issue":"2","key":"pone.0320937.ref018","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10194-006-0272-8","article-title":"High prolactin levels as a worsening factor for migraine","volume":"7","author":"C Cavestro","year":"2006","journal-title":"J Headache Pain"},{"issue":"2","key":"pone.0320937.ref019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"S Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"pone.0320937.ref020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"T Kvernmo","year":"2006","journal-title":"Clin Ther"},{"issue":"1","key":"pone.0320937.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"pone.0320937.ref022","doi-asserted-by":"crossref","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","article-title":"Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives","volume":"2","author":"TJ Mungoven","year":"2021","journal-title":"Front Pain Res (Lausanne)"},{"issue":"1","key":"pone.0320937.ref023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","article-title":"Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience","volume":"24","author":"B Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"issue":"2","key":"pone.0320937.ref024","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/0333102420960020","article-title":"The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments","volume":"41","author":"K Evans","year":"2021","journal-title":"Cephalalgia"},{"issue":"4","key":"pone.0320937.ref025","doi-asserted-by":"crossref","first-page":"e202907","DOI":"10.1001\/jamanetworkopen.2020.2907","article-title":"Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial","volume":"3","author":"AE Sanders","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"pone.0320937.ref026","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"F Vandervorst","year":"2021","journal-title":"J Headache Pain"},{"issue":"1","key":"pone.0320937.ref027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s10194-016-0696-8","article-title":"Risk of medication overuse headache across classes of treatments for acute migraine","volume":"17","author":"K Thorlund","year":"2016","journal-title":"J Headache Pain"},{"issue":"5","key":"pone.0320937.ref028","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"90","author":"R Steeds","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"pone.0320937.ref029","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints","volume":"106","author":"CE Stiles","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0320937.ref030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-09-0989","article-title":"Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline","volume":"162","author":"M Lafeber","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"pone.0320937.ref031","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.49.3.650","article-title":"Dopamine and migraine","volume":"49","author":"SJ Peroutka","year":"1997","journal-title":"Neurology"},{"issue":"11","key":"pone.0320937.ref032","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1177\/0333102420929023","article-title":"Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients","volume":"40","author":"P Barbanti","year":"2020","journal-title":"Cephalalgia"},{"issue":"3","key":"pone.0320937.ref033","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ana.21077","article-title":"Dopamine inhibits trigeminovascular transmission in the rat","volume":"61","author":"A Bergerot","year":"2007","journal-title":"Ann Neurol"},{"issue":"5","key":"pone.0320937.ref034","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/head.14412","article-title":"Prolactin in headache and migraine: A systematic review of preclinical studies","volume":"63","author":"MA-M Al-Karagholi","year":"2023","journal-title":"Headache"},{"issue":"9","key":"pone.0320937.ref035","doi-asserted-by":"crossref","first-page":"FSO748","DOI":"10.2144\/fsoa-2021-0047","article-title":"A link between migraine and prolactin: the way forward","volume":"7","author":"P Gazerani","year":"2021","journal-title":"Future Sci OA"},{"issue":"529","key":"pone.0320937.ref036","doi-asserted-by":"crossref","first-page":"eaay7550","DOI":"10.1126\/scitranslmed.aay7550","article-title":"The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females","volume":"12","author":"Y Chen","year":"2020","journal-title":"Sci Transl Med"},{"issue":"6","key":"pone.0320937.ref037","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ana.26070","article-title":"Meningeal CGRP-Prolactin Interaction Evokes Female-Specific Migraine Behavior","volume":"89","author":"A Avona","year":"2021","journal-title":"Ann Neurol"},{"issue":"48","key":"pone.0320937.ref038","doi-asserted-by":"crossref","first-page":"34943","DOI":"10.1074\/jbc.M113.486571","article-title":"Mechanisms of transient signaling via short and long prolactin receptor isoforms in female and male sensory neurons","volume":"288","author":"S Belugin","year":"2013","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0320937.ref039","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jpain.2022.02.006","article-title":"Migraine, Brain Glucose Metabolism and the \u201cNeuroenergetic\u201d Hypothesis: A Scoping Review","volume":"23","author":"L Del Moro","year":"2022","journal-title":"J Pain"},{"issue":"11","key":"pone.0320937.ref040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","article-title":"The metabolic face of migraine - from pathophysiology to treatment","volume":"15","author":"EC Gross","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"pone.0320937.ref041","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","article-title":"Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma","volume":"44","author":"SS Inancli","year":"2013","journal-title":"Endocrine"},{"issue":"4","key":"pone.0320937.ref042","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"CM dos Santos Silva","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"pone.0320937.ref043","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10194-022-01476-y","article-title":"Trends in utilization and costs of migraine medications, 2017-2020","volume":"23","author":"JL Nguyen","year":"2022","journal-title":"J Headache Pain"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:09:41Z","timestamp":1743541781000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320937"}},"subtitle":[],"editor":[{"given":"Sherief","family":"Ghozy,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320937","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}